Testosterone safety, efficacy data on Peyronie's treatment among sexual dysfunction research

This article is part of the State of Urology 2014

Dr. MulcahyThe safety of testosterone replacement therapy (TRT) has been the subject of two recently published studies, which were followed by a January 2014 FDA announcement that the agency is investigating the risk of stroke, heart attack, and death in men taking TRT. Additional data on the safety of TRT, including its use in men following radical prostatectomy, will be presented at the AUA meeting, said John J. Mulcahy, MD, PhD, a sexual medicine specialist in private practice in Madison, AL.

Dr. Mulcahy recommended that urologists keep an eye out for data on the efficacy of collagenase clostridium histolyticum (XIAFLEX), which was approved for the treatment of Peyronie’s disease late last year, and the erectile dysfunction drug avanafil (Stendra). Another noteworthy study will examine penile implant ectopic reservoir placement after robotic radical prostatectomy, he said.

His specific abstract recommendations are as follows:

PD22-02: Meaningful Change in Peyronie’s Disease Following Treatment With Collagenase Clostridium Histolyticum: Results From Two Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies
Wayne J.G. Hellstrom

PD20-05: Cost effectiveness of acute insertion of malleable penile prosthesis for refractory ischemic priapism in public hospital setting
Michael J. Belsante

MP48-02: Exercise improves the effect of testosterone replacement therapy and the durability of response after cessation of treatment
Min Gu Park

MP48-06: Hypogonadal men taking clomiphene citrate report similar satisfaction compred to men on testosterone replacement therapy
Ranjith Ramasamy

MP48-08: Safety of Testosterone Therapy in Men with Prostate Cancer
Ravi Kacker

MP48-11: Time to erectogenic effect of avanafil in a randomized, placebo-controlled trial
Wayne J.G. Hellstrom

Subscribe to Urology Times to get monthly news from the leading news source for urologists.